With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...
Harmony Garges, M.D, senior vice president, chief medical officer and head of global medical at ViiV Healthcare, highlighted ...
ViiV Healthcare, the specialist HIV company majority owned by GSK (LSE: GSK), today announced the presentation of new ...
Studies from OPERA and Trio cohorts provide further real-world evidence supporting CAB LA for PrEP’s high effectiveness and adherence in preventing HIV acquisition Patient-reported results for CAB LA ...
The survey also found that flexible and virtual appointments, as well as transportation support, were helpful while on ...
Cabotegravir – given the trade name Apretude – can be dosed just six times a year and showed superior results to daily, oral therapy with Gilead's widely used Truvada (emtricitabine and ...
GSK & ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024: London, UK Monday, October 14, 2024, 14:00 Hrs [IST] GSK plc and Vi ...
The result also keeps Gilead’s nose in front of its main rival in the HIV category, ViiV Healthcare, which has regulatory approval for an injectable PrEP option – Apretude (cabotegravir ...
It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback